Latest California Healthline Stories
KFF Health News' 'What the Health?': Democrats See Opportunity in GOP Threats to Repeal Health Law
Sensing that Republicans are walking into a political minefield by threatening once again to repeal the Affordable Care Act, the Biden administration is looking to capitalize by rolling out a series of initiatives aimed at high drug prices and other consequences of “corporate greed in health care.” Meanwhile, the Supreme Court hears a case that could determine when and how much victims of the opioid crisis can collect from Purdue Pharma, the drug company that lied about how addictive its drug, OxyContin, really was. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Rachana Pradhan of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann of KFF Health News’ sister podcast, “An Arm and a Leg,” about his investigation into hospitals suing their patients over unpaid bills.
Uncle Sam Wants You … to Help Stop Insurers’ Bogus Medicare Advantage Sales Tactics
The Biden administration wants to crack down on deceptive or misleading Medicare Advantage and drug plan sales tactics. It’s counting on beneficiaries to help catch offenders.
FTC Chief Gears Up for a Showdown With Private Equity
Lina Khan, chair of the FTC, says a recent lawsuit is meant to chill the consolidation of medical groups that results in higher prices for consumers. But it may be too late to curb price hikes.
Compensation Is Key to Fixing Primary Care Shortage
Many proposals have been floated about how to address the nation’s primary care problem. They range from training slots to medical school debt forgiveness but often sidestep comprehensive payment reform.
Why It’s So Tough to Reduce Unnecessary Medical Care
Treatments that don’t help patients, and may even harm them, are difficult to eliminate because they can be big sources of revenue.
A Peek at Big Pharma’s Playbook That Leaves Many Americans Unable to Afford Their Drugs
Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?
Sin barreras, los precios de algunos medicamentos existentes se han disparado, incluso cuando han caído drásticamente en otros países. Los nuevos medicamentos tienen precios enormes, respaldados por el lobby y el marketing.
Proposed Rule Would Make Hospital Prices Even More Transparent
A Biden administration proposal would help standardize the data on prices that hospitals provide to patients, increase its usefulness to consumers, and boost enforcement. Previous rules gave hospitals too many loopholes.
KFF Health News' 'What the Health?': Another Try for Mental Health ‘Parity’
President Joe Biden is kicking off his reelection campaign in part by trying to finish a decades-long effort to establish parity in insurance benefits between mental and physical health. Meanwhile, House Republicans are working to add abortion and other contentious amendments to must-pass spending bills. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Céline Gounder about her podcast “Epidemic.” The new season focuses on the successful public health effort to eradicate smallpox.
Everything Old Is New Again? The Latest Round of Health Policy Proposals Reprises Existing Ideas
House Republican legislation promises more health insurance options but fewer protections, even as the Biden administration seeks to rein in short-term plans, which were expanded in the Trump era.